+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Vaccines Market By Technology Type, By Indication, Polio, Hepatitis, Other Indications), By End User: Global Opportunity Analysis and Industry Forecast, 2024-2035

  • PDF Icon

    Report

  • 350 Pages
  • April 2024
  • Region: Global
  • Allied Market Research
  • ID: 6010415
UP TO OFF until Nov 15th 2024
The vaccine market was valued at $43.2 billion in 2023 and is projected to reach $90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine.

The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Technology Type

  • Inactivated Vaccines
  • Toxoid Vaccines
  • Others
  • Recombinant and Conjugate Vaccines
  • Live Attenuated Vaccines

By Indication

  • Pneumococcal Disease
  • Influenza
  • Human Papilloma Virus
  • Meningococcal Disease
  • Rotavirus
  • Varicella
  • Measles, Mumps, and Rubella
  • Diphtheria, Pertussis, and Tetanus (DTP)
  • Polio
  • Hepatitis
  • Other Indications

By End User

  • Pediatric
  • Adults
  • Travelers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key Market Players
  • CSL Limited
  • Emergent Bi
  • Solutions Inc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic
  • Zhi Fei Biological
  • Bharat Biotech

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Recombinant and Conjugate Vaccines
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Live Attenuated Vaccines
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Inactivated Vaccines
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Toxoid Vaccines
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: VACCINES MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Pneumococcal Disease
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Influenza
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Human Papilloma Virus
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Meningococcal Disease
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Rotavirus
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Varicella
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Measles, Mumps, and Rubella
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
5.9. Diphtheria, Pertussis, and Tetanus (DTP)
5.9.1. Key market trends, growth factors and opportunities
5.9.2. Market size and forecast, by region
5.9.3. Market share analysis by country
5.10. Polio
5.10.1. Key market trends, growth factors and opportunities
5.10.2. Market size and forecast, by region
5.10.3. Market share analysis by country
5.11. Hepatitis
5.11.1. Key market trends, growth factors and opportunities
5.11.2. Market size and forecast, by region
5.11.3. Market share analysis by country
5.12. Other Indications
5.12.1. Key market trends, growth factors and opportunities
5.12.2. Market size and forecast, by region
5.12.3. Market share analysis by country
CHAPTER 6: VACCINES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Adults
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Travelers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: VACCINES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Technology Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Technology Type
7.2.5.1.2. Market size and forecast, by Indication
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Technology Type
7.2.5.2.2. Market size and forecast, by Indication
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Technology Type
7.2.5.3.2. Market size and forecast, by Indication
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Technology Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Technology Type
7.3.5.1.2. Market size and forecast, by Indication
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.3.2. Market size and forecast, by Indication
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Technology Type
7.3.5.4.2. Market size and forecast, by Indication
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Technology Type
7.3.5.5.2. Market size and forecast, by Indication
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Technology Type
7.3.5.6.2. Market size and forecast, by Indication
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Technology Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Technology Type
7.4.5.1.2. Market size and forecast, by Indication
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Technology Type
7.4.5.2.2. Market size and forecast, by Indication
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Technology Type
7.4.5.3.2. Market size and forecast, by Indication
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Technology Type
7.4.5.4.2. Market size and forecast, by Indication
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Technology Type
7.4.5.5.2. Market size and forecast, by Indication
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Technology Type
7.4.5.6.2. Market size and forecast, by Indication
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Technology Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Technology Type
7.5.5.1.2. Market size and forecast, by Indication
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Technology Type
7.5.5.2.2. Market size and forecast, by Indication
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Technology Type
7.5.5.3.2. Market size and forecast, by Indication
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Technology Type
7.5.5.4.2. Market size and forecast, by Indication
7.5.5.4.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. CSL Limited
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Emergent Bio Solutions Inc.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. GlaxoSmithKline Plc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Merck & Co., Inc.
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Pfizer
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sanofi
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Serum Institute of India Pvt. Ltd.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Bavarian Nordic
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Zhi Fei Biological
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Bharat Biotech
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
List of Tables
Table 01. Global Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 02. Vaccines Market for Recombinant and Conjugate Vaccines, by Region, 2023-2035 ($Million)
Table 03. Vaccines Market for Live Attenuated Vaccines, by Region, 2023-2035 ($Million)
Table 04. Vaccines Market for Inactivated Vaccines, by Region, 2023-2035 ($Million)
Table 05. Vaccines Market for Toxoid Vaccines, by Region, 2023-2035 ($Million)
Table 06. Vaccines Market for Others, by Region, 2023-2035 ($Million)
Table 07. Global Vaccines Market, by Indication, 2023-2035 ($Million)
Table 08. Vaccines Market for Pneumococcal Disease, by Region, 2023-2035 ($Million)
Table 09. Vaccines Market for Influenza, by Region, 2023-2035 ($Million)
Table 10. Vaccines Market for Human Papilloma Virus, by Region, 2023-2035 ($Million)
Table 11. Vaccines Market for Meningococcal Disease, by Region, 2023-2035 ($Million)
Table 12. Vaccines Market for Rotavirus, by Region, 2023-2035 ($Million)
Table 13. Vaccines Market for Varicella, by Region, 2023-2035 ($Million)
Table 14. Vaccines Market for Measles, Mumps, and Rubella, by Region, 2023-2035 ($Million)
Table 15. Vaccines Market for Diphtheria, Pertussis, and Tetanus (Dtp), by Region, 2023-2035 ($Million)
Table 16. Vaccines Market for Polio, by Region, 2023-2035 ($Million)
Table 17. Vaccines Market for Hepatitis, by Region, 2023-2035 ($Million)
Table 18. Vaccines Market for Other Indications, by Region, 2023-2035 ($Million)
Table 19. Global Vaccines Market, by End-user, 2023-2035 ($Million)
Table 20. Vaccines Market for Pediatric, by Region, 2023-2035 ($Million)
Table 21. Vaccines Market for Adults, by Region, 2023-2035 ($Million)
Table 22. Vaccines Market for Travelers, by Region, 2023-2035 ($Million)
Table 23. Vaccines Market, by Region, 2023-2035 ($Million)
Table 24. North America Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 25. North America Vaccines Market, by Indication, 2023-2035 ($Million)
Table 26. North America Vaccines Market, by End-user, 2023-2035 ($Million)
Table 27. North America Vaccines Market, by Country, 2023-2035 ($Million)
Table 28. U.S. Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 29. U.S. Vaccines Market, by Indication, 2023-2035 ($Million)
Table 30. U.S. Vaccines Market, by End-user, 2023-2035 ($Million)
Table 31. Canada Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 32. Canada Vaccines Market, by Indication, 2023-2035 ($Million)
Table 33. Canada Vaccines Market, by End-user, 2023-2035 ($Million)
Table 34. Mexico Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 35. Mexico Vaccines Market, by Indication, 2023-2035 ($Million)
Table 36. Mexico Vaccines Market, by End-user, 2023-2035 ($Million)
Table 37. Europe Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 38. Europe Vaccines Market, by Indication, 2023-2035 ($Million)
Table 39. Europe Vaccines Market, by End-user, 2023-2035 ($Million)
Table 40. Europe Vaccines Market, by Country, 2023-2035 ($Million)
Table 41. Germany Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 42. Germany Vaccines Market, by Indication, 2023-2035 ($Million)
Table 43. Germany Vaccines Market, by End-user, 2023-2035 ($Million)
Table 44. France Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 45. France Vaccines Market, by Indication, 2023-2035 ($Million)
Table 46. France Vaccines Market, by End-user, 2023-2035 ($Million)
Table 47. UK Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 48. UK Vaccines Market, by Indication, 2023-2035 ($Million)
Table 49. UK Vaccines Market, by End-user, 2023-2035 ($Million)
Table 50. Italy Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 51. Italy Vaccines Market, by Indication, 2023-2035 ($Million)
Table 52. Italy Vaccines Market, by End-user, 2023-2035 ($Million)
Table 53. Spain Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 54. Spain Vaccines Market, by Indication, 2023-2035 ($Million)
Table 55. Spain Vaccines Market, by End-user, 2023-2035 ($Million)
Table 56. Rest of Europe Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 57. Rest of Europe Vaccines Market, by Indication, 2023-2035 ($Million)
Table 58. Rest of Europe Vaccines Market, by End-user, 2023-2035 ($Million)
Table 59. Asia-Pacific Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 60. Asia-Pacific Vaccines Market, by Indication, 2023-2035 ($Million)
Table 61. Asia-Pacific Vaccines Market, by End-user, 2023-2035 ($Million)
Table 62. Asia-Pacific Vaccines Market, by Country, 2023-2035 ($Million)
Table 63. Japan Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 64. Japan Vaccines Market, by Indication, 2023-2035 ($Million)
Table 65. Japan Vaccines Market, by End-user, 2023-2035 ($Million)
Table 66. China Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 67. China Vaccines Market, by Indication, 2023-2035 ($Million)
Table 68. China Vaccines Market, by End-user, 2023-2035 ($Million)
Table 69. India Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 70. India Vaccines Market, by Indication, 2023-2035 ($Million)
Table 71. India Vaccines Market, by End-user, 2023-2035 ($Million)
Table 72. Australia Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 73. Australia Vaccines Market, by Indication, 2023-2035 ($Million)
Table 74. Australia Vaccines Market, by End-user, 2023-2035 ($Million)
Table 75. South Korea Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 76. South Korea Vaccines Market, by Indication, 2023-2035 ($Million)
Table 77. South Korea Vaccines Market, by End-user, 2023-2035 ($Million)
Table 78. Rest of Asia-Pacific Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 79. Rest of Asia-Pacific Vaccines Market, by Indication, 2023-2035 ($Million)
Table 80. Rest of Asia-Pacific Vaccines Market, by End-user, 2023-2035 ($Million)
Table 81. LAMEA Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 82. LAMEA Vaccines Market, by Indication, 2023-2035 ($Million)
Table 83. LAMEA Vaccines Market, by End-user, 2023-2035 ($Million)
Table 84. LAMEA Vaccines Market, by Country, 2023-2035 ($Million)
Table 85. Brazil Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 86. Brazil Vaccines Market, by Indication, 2023-2035 ($Million)
Table 87. Brazil Vaccines Market, by End-user, 2023-2035 ($Million)
Table 88. Saudi Arabia Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 89. Saudi Arabia Vaccines Market, by Indication, 2023-2035 ($Million)
Table 90. Saudi Arabia Vaccines Market, by End-user, 2023-2035 ($Million)
Table 91. South Africa Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 92. South Africa Vaccines Market, by Indication, 2023-2035 ($Million)
Table 93. South Africa Vaccines Market, by End-user, 2023-2035 ($Million)
Table 94. Rest of LAMEA Vaccines Market, by Technology Type, 2023-2035 ($Million)
Table 95. Rest of LAMEA Vaccines Market, by Indication, 2023-2035 ($Million)
Table 96. Rest of LAMEA Vaccines Market, by End-user, 2023-2035 ($Million)
Table 97. Csl Limited: Key Executives
Table 98. Csl Limited: Company Snapshot
Table 99. Csl Limited: Product Segments
Table 100. Csl Limited: Service Segments
Table 101. Csl Limited: Product Portfolio
Table 102. Csl Limited: Key Strategies
Table 103. Emergent Bio Solutions Inc.: Key Executives
Table 104. Emergent Bio Solutions Inc.: Company Snapshot
Table 105. Emergent Bio Solutions Inc.: Product Segments
Table 106. Emergent Bio Solutions Inc.: Service Segments
Table 107. Emergent Bio Solutions Inc.: Product Portfolio
Table 108. Emergent Bio Solutions Inc.: Key Strategies
Table 109. GlaxoSmithKline PLC.: Key Executives
Table 110. GlaxoSmithKline PLC.: Company Snapshot
Table 111. GlaxoSmithKline PLC.: Product Segments
Table 112. GlaxoSmithKline PLC.: Service Segments
Table 113. GlaxoSmithKline PLC.: Product Portfolio
Table 114. GlaxoSmithKline PLC.: Key Strategies
Table 115. Merck & Co. Inc.: Key Executives
Table 116. Merck & Co. Inc.: Company Snapshot
Table 117. Merck & Co. Inc.: Product Segments
Table 118. Merck & Co. Inc.: Service Segments
Table 119. Merck & Co. Inc.: Product Portfolio
Table 120. Merck & Co. Inc.: Key Strategies
Table 121. Pfizer: Key Executives
Table 122. Pfizer: Company Snapshot
Table 123. Pfizer: Product Segments
Table 124. Pfizer: Service Segments
Table 125. Pfizer: Product Portfolio
Table 126. Pfizer: Key Strategies
Table 127. Sanofi: Key Executives
Table 128. Sanofi: Company Snapshot
Table 129. Sanofi: Product Segments
Table 130. Sanofi: Service Segments
Table 131. Sanofi: Product Portfolio
Table 132. Sanofi: Key Strategies
Table 133. Serum Institute of India Pvt. Ltd.: Key Executives
Table 134. Serum Institute of India Pvt. Ltd.: Company Snapshot
Table 135. Serum Institute of India Pvt. Ltd.: Product Segments
Table 136. Serum Institute of India Pvt. Ltd.: Service Segments
Table 137. Serum Institute of India Pvt. Ltd.: Product Portfolio
Table 138. Serum Institute of India Pvt. Ltd.: Key Strategies
Table 139. Bavarian Nordic: Key Executives
Table 140. Bavarian Nordic: Company Snapshot
Table 141. Bavarian Nordic: Product Segments
Table 142. Bavarian Nordic: Service Segments
Table 143. Bavarian Nordic: Product Portfolio
Table 144. Bavarian Nordic: Key Strategies
Table 145. Zhi Fei Biological: Key Executives
Table 146. Zhi Fei Biological: Company Snapshot
Table 147. Zhi Fei Biological: Product Segments
Table 148. Zhi Fei Biological: Service Segments
Table 149. Zhi Fei Biological: Product Portfolio
Table 150. Zhi Fei Biological: Key Strategies
Table 151. Bharat Biotech: Key Executives
Table 152. Bharat Biotech: Company Snapshot
Table 153. Bharat Biotech: Product Segments
Table 154. Bharat Biotech: Service Segments
Table 155. Bharat Biotech: Product Portfolio
Table 156. Bharat Biotech: Key Strategies
List of Figures
Figure 01. Vaccines Market, 2023-2035
Figure 02. Segmentation of Vaccines Market,2023-2035
Figure 03. Top Impacting Factors in Vaccines Market
Figure 04. Top Investment Pockets in Vaccines Market (2024-2035)
Figure 05. Bargaining Power of Suppliers
Figure 06. Bargaining Power of Buyers
Figure 07. Threat of Substitution
Figure 08. Threat of Substitution
Figure 09. Competitive Rivalry
Figure 10. Global Vaccines Market:Drivers, Restraints and Opportunities
Figure 11. Vaccines Market, by Technology Type, 2023 and 2035(%)
Figure 12. Comparative Share Analysis of Vaccines Market for Recombinant and Conjugate Vaccines, by Country 2023 and 2035(%)
Figure 13. Comparative Share Analysis of Vaccines Market for Live Attenuated Vaccines, by Country 2023 and 2035(%)
Figure 14. Comparative Share Analysis of Vaccines Market for Inactivated Vaccines, by Country 2023 and 2035(%)
Figure 15. Comparative Share Analysis of Vaccines Market for Toxoid Vaccines, by Country 2023 and 2035(%)
Figure 16. Comparative Share Analysis of Vaccines Market for Others, by Country 2023 and 2035(%)
Figure 17. Vaccines Market, by Indication, 2023 and 2035(%)
Figure 18. Comparative Share Analysis of Vaccines Market for Pneumococcal Disease, by Country 2023 and 2035(%)
Figure 19. Comparative Share Analysis of Vaccines Market for Influenza, by Country 2023 and 2035(%)
Figure 20. Comparative Share Analysis of Vaccines Market for Human Papilloma Virus, by Country 2023 and 2035(%)
Figure 21. Comparative Share Analysis of Vaccines Market for Meningococcal Disease, by Country 2023 and 2035(%)
Figure 22. Comparative Share Analysis of Vaccines Market for Rotavirus, by Country 2023 and 2035(%)
Figure 23. Comparative Share Analysis of Vaccines Market for Varicella, by Country 2023 and 2035(%)
Figure 24. Comparative Share Analysis of Vaccines Market for Measles, Mumps, and Rubella, by Country 2023 and 2035(%)
Figure 25. Comparative Share Analysis of Vaccines Market for Diphtheria, Pertussis, and Tetanus (Dtp), by Country 2023 and 2035(%)
Figure 26. Comparative Share Analysis of Vaccines Market for Polio, by Country 2023 and 2035(%)
Figure 27. Comparative Share Analysis of Vaccines Market for Hepatitis, by Country 2023 and 2035(%)
Figure 28. Comparative Share Analysis of Vaccines Market for Other Indications, by Country 2023 and 2035(%)
Figure 29. Vaccines Market, by End-user, 2023 and 2035(%)
Figure 30. Comparative Share Analysis of Vaccines Market for Pediatric, by Country 2023 and 2035(%)
Figure 31. Comparative Share Analysis of Vaccines Market for Adults, by Country 2023 and 2035(%)
Figure 32. Comparative Share Analysis of Vaccines Market for Travelers, by Country 2023 and 2035(%)
Figure 33. Vaccines Market by Region, 2023 and 2035(%)
Figure 34. U.S. Vaccines Market, 2023-2035 ($Million)
Figure 35. Canada Vaccines Market, 2023-2035 ($Million)
Figure 36. Mexico Vaccines Market, 2023-2035 ($Million)
Figure 37. Germany Vaccines Market, 2023-2035 ($Million)
Figure 38. France Vaccines Market, 2023-2035 ($Million)
Figure 39. UK Vaccines Market, 2023-2035 ($Million)
Figure 40. Italy Vaccines Market, 2023-2035 ($Million)
Figure 41. Spain Vaccines Market, 2023-2035 ($Million)
Figure 42. Rest of Europe Vaccines Market, 2023-2035 ($Million)
Figure 43. Japan Vaccines Market, 2023-2035 ($Million)
Figure 44. China Vaccines Market, 2023-2035 ($Million)
Figure 45. India Vaccines Market, 2023-2035 ($Million)
Figure 46. Australia Vaccines Market, 2023-2035 ($Million)
Figure 47. South Korea Vaccines Market, 2023-2035 ($Million)
Figure 48. Rest of Asia-Pacific Vaccines Market, 2023-2035 ($Million)
Figure 49. Brazil Vaccines Market, 2023-2035 ($Million)
Figure 50. Saudi Arabia Vaccines Market, 2023-2035 ($Million)
Figure 51. South Africa Vaccines Market, 2023-2035 ($Million)
Figure 52. Rest of LAMEA Vaccines Market, 2023-2035 ($Million)
Figure 53. Top Winning Strategies, by Year
Figure 54. Top Winning Strategies, by Development
Figure 55. Top Winning Strategies, by Company
Figure 56. Product Mapping of Top 10 Players
Figure 57. Competitive Dashboard
Figure 58. Competitive Heatmap: Vaccines Market
Figure 59. Top Player Positioning, 2023

Companies Mentioned

Key Market Players in the Vaccines Market include:
  • CSL Limited
  • Emergent Bio Solutions Inc.
  • GlaxoSmithKline Plc.
  • Merck & Co. Inc.
  • Pfizer
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic
  • Zhi Fei Biological
  • Bharat Biotech

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information